SCHEMBL1895553

SCHEMBL1895553

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)C1c1ccccc1Cl

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.37
TP53 P04637 2/20 0.35
EPHX2 P34913 1/20 0.34
KMT2A Q03164 1/20 0.34
RECQL P46063 1/20 0.34
ACHE P22303 1/20 0.33
GAA P10253 2/20 0.33
CHRNA7 P36544 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1896038 0.90 ACHE (0.34) HSD11B1EPHX2RECQLACHEALDH1A1
SCHEMBL1895147 0.88 EPHX2 (0.34) HSD11B1EPHX2RECQL
SCHEMBL1898138 0.84 EPHX2 (0.45) HSD11B1EPHX2KMT2AALDH1A1
SCHEMBL1896854 0.82 HSD11B1 (0.48) HSD11B1EPHX2ACHEKDM4EALDH1A1
SCHEMBL1895704 0.82 HSD11B1 (0.55) HSD11B1
SCHEMBL1898633 0.81 TP53 (0.35) HSD11B1TP53EPHX2KMT2AGAA
SCHEMBL11976945 0.81 HSD11B1 (0.33) HSD11B1ACHE
SCHEMBL11975554 0.81 HSD11B1 (0.33) HSD11B1ACHE
SCHEMBL1898143 0.81 HSD11B1 (0.42) HSD11B1EPHX2
SCHEMBL1896531 0.80 P2RX7 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236789-B2 1-adamantyl azetidin-2-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-07 US claimed
EP-2322505-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME Kowa Company, Ltd. (JP) 2011-05-18 EP claimed
US-20100075943-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD., (JP) 2010-03-25 US claimed
US-8236789-B2 1-adamantyl azetidin-2-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-07 US disclosed
US-8236789-B2 1-adamantyl azetidin-2-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-07 US disclosed
EP-2322505-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME Kowa Company, Ltd. (JP) 2011-05-18 EP disclosed
US-20100075943-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD., (JP) 2010-03-25 US disclosed
US-20100075943-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD., (JP) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075943-A1 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD3B1, CYP46A1 HSD11B1 1/4885TP53 4190/4885EPHX2 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.